Express News | HC Wainwright & Co. Reiterates Buy on Annovis Bio, Maintains $30 Price Target

Benzinga37minutes ago

Annovis Bio Says US FDA Approved Use of Neurodegeneration Drug Buntanetap in Crystalline Form

Annovis Bio (ANVS) said Tuesday that the US Food and Drug Administration has granted the company approval to use a new crystalline form of its neurodegeneration drug buntanetap in future clinical

MT NewswiresJul 16 08:39 ET

Express News | Annovis Bio Granted FDA Approval To Transition To New Crystal Form Of Buntanetap

BenzingaJul 16 08:00 ET

Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap

Tue, 16 Jul 2024MALVERN, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug

Annovis BioJul 16 00:00 ET

Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Morgan

BenzingaJul 11 08:47 ET

H.C. Wainwright Maintains Annovis Bio(ANVS.US) With Buy Rating, Raises Target Price to $30

H.C. Wainwright analyst Ram Selvaraju maintains $Annovis Bio(ANVS.US)$ with a buy rating, and adjusts the target price from $23 to $30.According to TipRanks data, the analyst has a success rate of 39.

Moomoo NewsJul 11 08:31 ET · Ratings